A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.
Also called NCT07564414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,500 participants
- Sponsor
- Registry
-
NCT07564414
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07564414. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-21 (actual); primary completion 2028-02-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Condition
- Obesity
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Cagrisema
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07564414- Content hash
7d7075abd9009fb3695002cd7be5808cb8a044113247752764edb90cbb23cf4d